Last Updated : January 22, 2025
Details
Generic Name:
nemolizumab
Project Status:
Active
Therapeutic Area:
Prurigo nodularis (PN)
Manufacturer:
Galderma Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0861-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of moderate-to-severe prurigo nodularis (PN).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of moderate-to-severe prurigo nodularis (PN).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | November 21, 2024 |
|---|---|
| Call for patient/clinician input closed | January 17, 2025 |
| Submission received | January 07, 2025 |
| Submission accepted | January 21, 2025 |
| Review initiated | January 22, 2025 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | April 09, 2025 |
| Deadline for sponsors comments | April 22, 2025 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | May 15, 2025 |
| Expert committee meeting (initial) | May 28, 2025 |
| Draft recommendation issued to sponsor | June 09, 2025 To June 11, 2025 |
| Draft recommendation posted for stakeholder feedback | June 19, 2025 |
| End of feedback period | July 04, 2025 |
Last Updated : January 22, 2025